Cooley advised the underwriters in argenx’s $805 million follow-on offering of 2,683,334 ordinary shares, including ordinary shares represented by American Depositary Shares, at a public offering price of $300.00 per share. JP Morgan, Morgan Stanley, Cowen and SVB Leerink acted as joint bookrunners for the offering. argenx is a commericial-stage biotechnology company developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Partners Rich Segal and Div Gupta led the Cooley team.